Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.72 |
| ▸ | MEN1 | O00255 | 1/20 | 0.72 |
| ▸ | ABL1 | P00519 | 1/20 | 0.72 |
| ▸ | LMNA | P02545 | 1/20 | 0.72 |
| ▸ | PKM | P14618 | 1/20 | 0.72 |
| ▸ | IDE | P14735 | 1/20 | 0.72 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.72 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.72 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.72 |
| ▸ | HLCS | P50747 | 4/20 | 0.52 |
| ▸ | CA12 | O43570 | 8/20 | 0.52 |
| ▸ | CA1 | P00915 | 8/20 | 0.52 |
| ▸ | CA2 | P00918 | 8/20 | 0.52 |
| ▸ | CA9 | Q16790 | 8/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Biotin SCHEMBL438197 | 0.99 | TDP1 (0.74) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL2484400 | 0.90 | TDP1 (0.69) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL1269623 | 0.90 | TDP1 (0.60) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL3378125 | 0.89 | TDP1 (0.79) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL3142794 | 0.86 | TDP1 (0.71) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL6930604 | 0.86 | TDP1 (0.97) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL723192 | 0.85 | TDP1 (0.90) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL1199492 | 0.85 | TDP1 (0.94) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL636444 | 0.85 | TDP1 (0.94) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL23055065 | 0.85 | TDP1 (1.00) | TDP1MEN1ABL1LMNAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240139288-A1 | LIPID-BASED NANOPARTICLES AND USE OF SAME IN OPTIMIZED INSULIN DOSING REGIMENS | SDG INC (US) | 2024-05-02 | — | — | US | claimed |
| US-20240108585-A1 | COMPOSITIONS COMPRISING LIPID-BASED NANOPARTICLES FOR TREATING DIABETES MELLITUS | SDG, INC. | 2024-04-04 | — | — | US | claimed |
| EP-2552202-B1 | METHODS AND COMPOSITIONS FOR WEIGHT LOSS | SDG INC (US) | 2023-07-26 | — | — | EP | claimed |
| US-20230172868-A1 | LIPID-BASED NANOPARTICLES WITH ENHANCED STABILITY | SDG, INC. (US) | 2023-06-08 | — | — | US | claimed |
| US-11517529-B2 | Orally bioavailable lipid-based constructs | SDG, INC. (US) | 2022-12-06 | — | — | US | claimed |
| EP-3952904-A1 | LIPID-BASED NANOPARTICLES AND USE OF SAME IN OPTIMIZED INSULIN DOSING REGIMENS | SDG, Inc. (US) | 2022-02-16 | — | — | EP | claimed |
| US-20210379160-A1 | LIPID-BASED NANOPARTICLES AND USE OF SAME IN OPTIMIZED INSULIN DOSING REGIMENS | SDG INC (US) | 2021-12-09 | — | — | US | claimed |
| US-11077173-B2 | Lipid-based nanoparticles and methods using same | SDG, INC. (US) | 2021-08-03 | — | — | US | claimed |
| US-11071715-B2 | Lipid-based nanoparticles and methods using same | SDG, INC. (US) | 2021-07-27 | — | — | US | claimed |
| US-20210137838-A1 | LIPID-BASED NANOPARTICLES WITH ENHANCED STABILITY | SDG, INC. | 2021-05-13 | — | — | US | claimed |
| US-20100310599-A1 | Orally Bioavailable Lipid-Based Constructs | SDG, INC. | 2010-12-09 | — | — | US | claimed |
| US-20100247625-A1 | Orally Bioavailable Lipid-Based Constructs | SDG, INC. | 2010-09-30 | — | — | US | claimed |
| EP-2205217-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | SDG, INC. (an Ohio Corporation ) (US) | 2010-07-14 | — | — | EP | claimed |
| US-20100129428-A1 | SUPRA MOLECULAR CONSTRUCT FOR DELIVERY OF INTERFERON TO A MAMMAL | SDG, INC. | 2010-05-27 | — | — | US | claimed |
| US-20090087479-A1 | Orally bioavailable lipid-based constructs | SDG, INC. ( AN OHIO CORPORATION) (US) | 2009-04-02 | — | — | US | claimed |
| WO-2009042945-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | SDG, INC. (AN OHIO CORPORATION ) (US) | 2009-04-02 | — | — | WO | claimed |
| EP-1883394-A2 | LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL | SDG, Inc. (US) | 2008-02-06 | — | — | EP | claimed |
| EP-1883395-A2 | LIPID CONSTRUCT FOR DELIVERY OF INTERFERON TO A MAMMAL | SDG, Inc. (US) | 2008-02-06 | — | — | EP | claimed |
| WO-2006127361-A2 | LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL | SDG, INC. (US) | 2006-11-30 | — | — | WO | claimed |
| WO-2006127360-A2 | LIPID CONSTRUCT FOR DELIVERY OF INTERFERON TO A MAMMAL | SDG, INC. (US) | 2006-11-30 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210379160-A1 | LIPID-BASED NANOPARTICLES AND USE OF SAME IN OPTIMIZED INSULIN DOSING REGIMENS | PNLIP, IAPP, LIPC | TDP1 4800/4885MEN1 561/4885ABL1 2416/4885 |
| US-20100129428-A1 | SUPRA MOLECULAR CONSTRUCT FOR DELIVERY OF INTERFERON TO A MAMMAL | HAVCR2, IFNAR1, IFNG | TDP1 4713/4885MEN1 4095/4885ABL1 2883/4885 |
| US-20240108585-A1 | COMPOSITIONS COMPRISING LIPID-BASED NANOPARTICLES FOR TREATING DIABETES MELLITUS | IAPP, PNLIP, LIPC | TDP1 4738/4885MEN1 1515/4885ABL1 2221/4885 |
| US-20100310599-A1 | Orally Bioavailable Lipid-Based Constructs | FABP2, LIPC, FABP6 | TDP1 4650/4885MEN1 1077/4885ABL1 3190/4885 |
| US-20230172868-A1 | LIPID-BASED NANOPARTICLES WITH ENHANCED STABILITY | LIPA, NPC1L1, PLIN3 | TDP1 3561/4885MEN1 1725/4885ABL1 2117/4885 |
| US-11517529-B2 | Orally bioavailable lipid-based constructs | FABP2, FABP1, FABP6 | TDP1 4819/4885MEN1 966/4885ABL1 4375/4885 |
| US-11077173-B2 | Lipid-based nanoparticles and methods using same | LIPA, PLIN3, CETP | TDP1 2457/4885MEN1 2345/4885ABL1 1844/4885 |
| US-20090087479-A1 | Orally bioavailable lipid-based constructs | FABP2, FABP1, FABP6 | TDP1 4757/4885MEN1 1343/4885ABL1 3225/4885 |
| US-20210137838-A1 | LIPID-BASED NANOPARTICLES WITH ENHANCED STABILITY | LIPA, NPC1L1, PLIN3 | TDP1 3561/4885MEN1 1725/4885ABL1 2117/4885 |
| US-11071715-B2 | Lipid-based nanoparticles and methods using same | LIPA, PLIN3, CETP | TDP1 2457/4885MEN1 2345/4885ABL1 1844/4885 |
| US-20100247625-A1 | Orally Bioavailable Lipid-Based Constructs | FABP2, LIPC, FABP6 | TDP1 4650/4885MEN1 1077/4885ABL1 3190/4885 |
| US-20240139288-A1 | LIPID-BASED NANOPARTICLES AND USE OF SAME IN OPTIMIZED INSULIN DOSING REGIMENS | PNLIP, IAPP, LIPC | TDP1 4800/4885MEN1 561/4885ABL1 2416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.